Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

NCT01682044 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Roswell Park Cancer Institute

Collaborators